TransTech Pharma.

PositionTRIAD

HIGH POINT -- Drug developer TransTech Pharma signed a $155 million licensing agreement under which New York-based drug maker Pfizer will develop and commercialize a TransTech compound that could be used to treat Alzheimer's disease. TransTech also will get up to $18 million...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT